Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with BMS to Discover and Develop Next-Gen Multi-Specific Antibodies
Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented: “We are delighted to collaborate with Bristol Myers Squibb to advance next-generation multi-specific antibody discovery and development. This collaboration leverages our Harbour Mice® fully human antibody technology platform, which facilitates the efficient discovery and development of innovative biologics with enhanced therapeutic potential. Furthermore, the collaboration offers the possibility to utilize our established development capabilities to accelerate programs by conducting early clinical trials in China. By uniting the strengths of our platform with Bristol Myers Squibb’s expertise in drug discovery and development, we look forward to progressing these programs and delivering transformative therapies to patients worldwide.”
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000